We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

Back to rankings

142 hedge funds and large institutions have $422M invested in Sciclone Pharmaceuticals Inc in 2017 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 56 increasing their positions, 39 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 39

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

15% more capital invested

Capital invested by funds: $366M → $422M (+$55.6M)

4% more funds holding

Funds holding: 136 → 142 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

82% less call options, than puts

Call options by funds: $214K | Put options by funds: $1.17M

Holders
142
Holders Change
+6
Holders Change %
+4.41%
% of All Funds
3.54%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
24
Increased
56
Reduced
39
Closed
18
Calls
$214K
Puts
$1.17M
Net Calls
-$959K
Net Calls Change
-$983K

Top Buyers

Rank Fund Capital Flow
1
GP
GLG Partners
United Kingdom
+$12.3M
2
Two Sigma Investments
Two Sigma Investments
New York
+$6.99M
3
Renaissance Technologies
Renaissance Technologies
New York
+$4.56M
4
OAM
Oxford Asset Management
United Kingdom
+$4M
5
GH
GAM Holding
Switzerland
+$3.87M

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$18.5M
2
SCM
Stonepine Capital Management
Oregon
-$14.5M
3
PRCM
Pine River Capital Management
Minnesota
-$3.98M
4
BlackRock
BlackRock
New York
-$2.45M
5
SFM
Systematic Financial Management
New Jersey
-$1.32M
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$3.42M +$2.5M +250,256 +413%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$3.15M +$104K +10,419 +4%
AC
28
Athos Capital
Hong Kong
$3.13M +$2.84M +284,200 New
Ameriprise
29
Ameriprise
Minnesota
$3.11M -$72.2K -7,215 -2%
CS
30
Credit Suisse
Switzerland
$3.08M +$986K +98,595 +54%
GT
31
Glenmede Trust
Pennsylvania
$2.99M – – –
Allianz Asset Management
32
Allianz Asset Management
Germany
$2.93M +$1.48M +147,947 +124%
TCIM
33
TIAA CREF Investment Management
New York
$2.84M -$32.6K -3,261 -1%
Skandinaviska Enskilda Banken (SEB)
34
Skandinaviska Enskilda Banken (SEB)
Sweden
$2.82M +$77K +7,700 +3%
GC
35
Guggenheim Capital
Illinois
$2.71M +$807K +80,709 +49%
MWNA
36
Marshall Wace North America
New York
$2.67M +$2.23M +223,144 +1,142%
AllianceBernstein
37
AllianceBernstein
Tennessee
$2.58M +$467K +46,680 +25%
WAM
38
Wolverine Asset Management
Illinois
$2.52M +$2.29M +229,207 New
Fisher Asset Management
39
Fisher Asset Management
Washington
$2.49M +$707K +70,712 +45%
SCM
40
Stonepine Capital Management
Oregon
$2.38M -$14.5M -1,446,974 -87%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$2.12M +$1.93M +193,000 New
Invesco
42
Invesco
Georgia
$1.84M +$139K +13,914 +9%
GCP
43
GSA Capital Partners
United Kingdom
$1.84M -$729K -72,900 -30%
UBS Group
44
UBS Group
Switzerland
$1.77M +$1.61M +160,879 +211,683%
Russell Investments Group
45
Russell Investments Group
United Kingdom
$1.58M -$181K -18,136 -11%
RIM
46
Ranger Investment Management
Texas
$1.58M – – –
PPA
47
Parametric Portfolio Associates
Washington
$1.21M +$114K +11,355 +11%
CCMH
48
Cornerstone Capital Management Holdings
New York
$1.2M -$1.06M -105,696 -49%
Citigroup
49
Citigroup
New York
$1.19M +$387K +38,727 +56%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$1.17M +$48.6K +4,863 +5%
1
2
3 4 5

SCLN Hedge Fund Activity: Q2 2017 in Review

142 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q2 2017, worth a combined $422M — up 15% from $366M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SCLN positions and 18 closed out — a net gain of 6 holders — while 56 added to existing stakes and 39 trimmed.

The largest buyer was GLG Partners, adding an estimated $12.3M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $18.5M sold.

  • 142 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q2 2017, up from 136 in Q1 2017.
  • Funds reported $422M of Sciclone Pharmaceuticals Inc stock for Q2 2017, up 15% quarter-over-quarter.
  • 24 funds opened new Sciclone Pharmaceuticals Inc positions in Q2 2017 and 18 closed out, a net change of +6 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q2 2017 was GLG Partners, an estimated $12.3M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q2 2017 was Nantahala Capital Management, an estimated $18.5M sold.

Based on aggregated 13F filings for Q2 2017.